(Q39405474)

11 September 2017

title

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial (English)

1 reference

gastroesophageal reflux disease

11 September 2017

0 references

0 references

(RS)-rabeprazole

0 references

author name string

Philip Miner

1

1 reference

11 September 2017

William Orr

2

1 reference

11 September 2017

Joseph Filippone

3

1 reference

11 September 2017

Leonard Jokubaitis

4

1 reference

11 September 2017

Sheldon Sloan

5

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

The American Journal of Gastroenterology

11 September 2017

published in

1 reference

11 September 2017

volume

97

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

1332-1339

1 reference

Gastroesophageal reflux: practical management of a common, challenging disorder

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Nonerosive reflux disease--current concepts and dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05769.X

10.1111/J.1572-0241.2002.05769.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference